Home » Merck’s Keytruda Combo Therapy OK’d by European Commission
Merck’s Keytruda Combo Therapy OK’d by European Commission
The European Commission gave the green light for Merck’s Keytruda, granting it EU approval for first-line treatment of lung cancer patients in combination with Pemetrexed and platinum chemotherapy.
The anti-PD-1 therapy is approved for patients with nonsquamous non-small cell lung cancer (NSCLC) in adults whose tumors do not have EGFR or ALK positive mutations.
The Phase 3 Keynote-189 trial showed a significant survival benefit when using Keytruda with chemotherapy as opposed to standard-of-care chemotherapy by itself.
Upcoming Events
-
07May
-
14May
-
30May